fda status bpc-157 2026 When will the reclassify to Category 1? Odds & Predictions FDA Panel to Review 7
Description
Individuals with weakened immune systems or those prone to frequent infections can benefit from the immune-modulating effects of peptide therapy
As a cofactor, it participates in many biochemical processes related to the nervous system, supporting neurotransmitters like dopamine and serotonin
However, these theoretical advantages are irrelevant without human efficacy data
I decided to give it a try and Im glad I did
At this time, low-level laser therapy (LLLT) and photobiomodulation are cleared by the FDA for improving circulation and reducing pain, but not specifically for reversing neuropathy
